Background: COVID-2019 pandemic lead to a raised interest on the development of new treatments through Artificial Intelligence (AI). Aim: to carry out a systematic review on the development of repurposed drugs against COVID-2019 through the application of AI. Methods: The Systematic Reviews and Meta-Analyses (PRISMA) checklist was applied. Keywords: [“Artificial intelligence” and (COVID or SARS) and (medicine or drug)]. Databases: PubMed ® , DOAJ and SciELO. Cochrane Library was additionally screened to identify previous published reviews on the same topic. Results: From the 277 identified records [PubMed ® (n = 157); DOAJ ( n = 119) and SciELO ( n = 1)], 27 studies were included. Among other, the selected studies on new treatments against COVID-2019 were classified, as follows: studies with in-vitro and/or clinical data; association of known drugs; and other studies related to repurposing of drugs. Conclusion: Diverse potentially repurposed drugs against COVID-2019 were identified. The repurposed drugs were mainly from antivirals, antibiotics, anticancer, anti-inflammatory, and Angiotensin-converting enzyme 2 (ACE2) groups, although diverse other pharmacologic groups were covered. AI was a suitable tool to quickly analyze large amounts of data or to estimate drug repurposing against COVID-2019.
【저자키워드】 SARS-CoV-2, drug design, artificial intelligence, machine learning, molecular docking, molecular dynamics, COVID-2019, In silico methods, Repurposing of drugs, Medicines, 【초록키워드】 Treatment, review, ACE2, pandemic, Anti-inflammatory, antivirals, drugs, systematic review, Antibiotics, COVID, Repurposed drug, artificial, group, association, In-vitro, Topic, enzyme, Cochrane Library, anticancer, intelligence, SciELO, selected, identify, raised, applied, screened, groups, 【제목키워드】 review, Medicine, artificial, development, intelligence,